[go: up one dir, main page]

PE20200863A1 - Preparacion de absorcion percutanea que comprende donepezilo, monocaprilato de propilenglicol y copolimero de bloque de estireno-isopreno-estireno para la prevencion de la demencia causada por alzheimer - Google Patents

Preparacion de absorcion percutanea que comprende donepezilo, monocaprilato de propilenglicol y copolimero de bloque de estireno-isopreno-estireno para la prevencion de la demencia causada por alzheimer

Info

Publication number
PE20200863A1
PE20200863A1 PE2020000868A PE2020000868A PE20200863A1 PE 20200863 A1 PE20200863 A1 PE 20200863A1 PE 2020000868 A PE2020000868 A PE 2020000868A PE 2020000868 A PE2020000868 A PE 2020000868A PE 20200863 A1 PE20200863 A1 PE 20200863A1
Authority
PE
Peru
Prior art keywords
styrene
drug
propylene glycol
containing layer
isoprene
Prior art date
Application number
PE2020000868A
Other languages
English (en)
Inventor
Sun-Woo Jang
Chang-Yell Shin
Jeong-Soo Kim
Hae-Sun Kim
Kwang-Ho Cha
Hyun-Jung Kim
Masaoki Goto
Original Assignee
Dong A St Co Ltd
Km Transderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd, Km Transderm Ltd filed Critical Dong A St Co Ltd
Publication of PE20200863A1 publication Critical patent/PE20200863A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D7/00—Producing flat articles, e.g. films or sheets
    • B29D7/01—Films or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a una preparacion de absorcion percutanea que comprende una capa de soporte, una capa que contiene el farmaco y un protector adherente, en donde la capa que contiene el farmaco comprende: a) donepezilo o una sal farmaceuticamente aceptable del mismo, b) monocaprilato de propilenglicol como solubilizante, en una cantidad de 1-40% en peso de la capa que contiene el farmaco, c) copolimero del bloque de de estireno-isopreno-estireno ("SIS") como adhesivo, en una cantidad de 10-70% en peso de la capa que contiene el farmaco, y d) un plastificante tal como propilenglicol, aceite de oliva, entre otros. Tambien se refiere a su proceso de preparacion, el cual comprende las siguientes etapas: a) disolucion del monocaprilato de propilenglicol, del copolimero de bloque de estierno-isopreno-estireno y de la base libre de donepezilo en un disolvente organico, b) moldeo de la solucion obtenida en la etapa (a) sobre un protector antiadherente, seguido de secado, para formar una capa que contenga el farmaco; c) laminacion de la capa que contiene el farmaco con una capa de soporte. La preparacion de absorcion percutanea segun la presente invencion tiene baja irritacion de piel y alta penetracion en la piel.
PE2020000868A 2017-12-27 2018-11-07 Preparacion de absorcion percutanea que comprende donepezilo, monocaprilato de propilenglicol y copolimero de bloque de estireno-isopreno-estireno para la prevencion de la demencia causada por alzheimer PE20200863A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170180647A KR102024996B1 (ko) 2017-12-27 2017-12-27 도네페질을 함유하는 치매 치료용 경피흡수제제
PCT/KR2018/013439 WO2019132229A1 (ko) 2017-12-27 2018-11-07 도네페질을 함유하는 치매 치료용 경피흡수제제

Publications (1)

Publication Number Publication Date
PE20200863A1 true PE20200863A1 (es) 2020-08-25

Family

ID=67067659

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000868A PE20200863A1 (es) 2017-12-27 2018-11-07 Preparacion de absorcion percutanea que comprende donepezilo, monocaprilato de propilenglicol y copolimero de bloque de estireno-isopreno-estireno para la prevencion de la demencia causada por alzheimer

Country Status (16)

Country Link
US (1) US11992562B2 (es)
EP (1) EP3733168A4 (es)
JP (1) JP7170728B2 (es)
KR (1) KR102024996B1 (es)
CN (1) CN111542311B (es)
AU (1) AU2018395643B2 (es)
BR (1) BR112020013187A2 (es)
CA (1) CA3087156C (es)
CL (1) CL2020001738A1 (es)
MA (1) MA50116B2 (es)
MX (1) MX2020006645A (es)
PE (1) PE20200863A1 (es)
PH (1) PH12020500568A1 (es)
SA (1) SA520412324B1 (es)
WO (1) WO2019132229A1 (es)
ZA (1) ZA202004530B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102218593B1 (ko) 2020-05-13 2021-02-22 동아에스티 주식회사 안정성이 향상된 도네페질 함유 경피 흡수제제
KR102489860B1 (ko) * 2021-09-02 2023-01-19 동아에스티 주식회사 메만틴 에난트산염을 포함하는 치매 치료용 경피흡수 제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3987655B2 (ja) 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
CN1571664A (zh) * 2001-10-17 2005-01-26 久光制药株式会社 经皮吸收型制剂
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
DE602005010812D1 (de) * 2004-11-22 2008-12-18 Hisamitsu Pharmaceutical Co Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff
TW200838479A (en) * 2006-12-01 2008-10-01 Nitto Denko Corp Percutaneously absorbable preparation
KR101454362B1 (ko) * 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2328582A4 (en) 2008-09-30 2012-02-22 Teikoku Pharma Usa Inc DERPEZIL COMPOSITIONS WITH EXTENDED TRANSDERMAL DELIVERY AND METHODS OF USE
CN102630160B (zh) 2009-09-16 2014-05-07 株式会社三养生物制药 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法
RU2545696C2 (ru) * 2009-10-21 2015-04-10 Тейкоку Сейяку Ко., Лтд. Трансдермально абсорбируемый состав, содержащий донепезил
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
US20130053358A1 (en) * 2010-04-28 2013-02-28 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
US20130224262A1 (en) 2010-09-03 2013-08-29 Medrx Co., Ltd. Transdermal preparation
WO2013035850A1 (ja) * 2011-09-08 2013-03-14 株式会社 ケイ・エム トランスダーム 経皮吸収製剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
KR20160120778A (ko) * 2014-02-20 2016-10-18 날 파마슈티칼 그룹 리미티드 도네페질을 함유하는 경피흡수제제
CA2970276C (en) * 2014-12-18 2023-08-01 Icure Pharmaceutical, Inc Transdermal composition containing donepezil as active ingredient
WO2019142940A1 (ja) * 2018-01-22 2019-07-25 株式会社カネカ 皮膚貼付用粘着シート

Also Published As

Publication number Publication date
AU2018395643B2 (en) 2023-02-16
CA3087156A1 (en) 2019-07-04
JP2021508713A (ja) 2021-03-11
KR102024996B1 (ko) 2019-09-25
RU2020123498A (ru) 2022-01-27
MX2020006645A (es) 2020-11-06
WO2019132229A1 (ko) 2019-07-04
EP3733168A4 (en) 2021-09-08
RU2020123498A3 (es) 2022-01-27
EP3733168A1 (en) 2020-11-04
KR20190078893A (ko) 2019-07-05
ZA202004530B (en) 2021-09-29
MA50116A1 (fr) 2021-09-30
CA3087156C (en) 2023-08-01
CL2020001738A1 (es) 2020-11-06
US11992562B2 (en) 2024-05-28
US20210059956A1 (en) 2021-03-04
CN111542311B (zh) 2023-07-14
AU2018395643A1 (en) 2020-07-02
BR112020013187A2 (pt) 2020-12-01
MA50116B2 (fr) 2023-03-31
CN111542311A (zh) 2020-08-14
JP7170728B2 (ja) 2022-11-14
PH12020500568A1 (en) 2021-04-19
SA520412324B1 (ar) 2024-10-07

Similar Documents

Publication Publication Date Title
CL2022000250A1 (es) Molécula de unión al antígeno multiespecífica que tiene actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii) y formulación farmacéutica que contiene tal molécula como ingrediente activo (divisional de la solicitud n°202000767)
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
PE20200863A1 (es) Preparacion de absorcion percutanea que comprende donepezilo, monocaprilato de propilenglicol y copolimero de bloque de estireno-isopreno-estireno para la prevencion de la demencia causada por alzheimer
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
PE20161385A1 (es) Formulacion inmunosupresora
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
PE20180026A1 (es) Composicion topica curativa
MX390536B (es) Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico.
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CL2019000624A1 (es) Formulaciones de buprenorfina de liberación sostenida.
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
CO7560107A1 (es) Composición antitranspirante
CO2017013305A2 (es) Composiciones farmacéuticas sólidas de dos capas para el tratamiento de vhc
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
ECSP16069947A (es) Formulaciones tópicas de heparina
NI201900109A (es) Parche que contiene rupatadina
CL2019001555A1 (es) Preparación farmacéutica y método para su fabricación.
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina